Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report

Alectinib is a selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor as standard therapy for ALK-rearranged non-small cell lung cancer (NSCLC). Hemolytic anemia is considered as a rare but significant adverse event with alectinib. Here, we report a case of a 73-year-old female with lu...

Descripción completa

Detalles Bibliográficos
Autores principales: Misawa, Kazuhito, Nakamichi, Shinji, Iida, Hiroki, Nagano, Atsuhiro, Mikami, Erika, Tozuka, Takehiro, Matsumoto, Masaru, Miyanaga, Akihiko, Noro, Rintaro, Kubota, Kaoru, Yamaguchi, Hiroki, Seike, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884059/
https://www.ncbi.nlm.nih.gov/pubmed/36718244
http://dx.doi.org/10.2147/OTT.S398375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884059/
https://www.ncbi.nlm.nih.gov/pubmed/36718244
http://dx.doi.org/10.2147/OTT.S398375

Ejemplares similares